Skip to content
value.today

Biofrontera Inc.

Total raised
$15 M
1 round on record
Latest round
$15 M
Nov 2021
First round on record
Nov 2021
Today
Went public
See the company page

Biofrontera Inc. is listed today as Biofrontera Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 5 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Biofrontera Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2025$11 MPrivate placement after listing$10 to $50 million

Biofrontera Inc.: Private sale, Jun 2025

Investors in this round

5 investors had bought by the notice of Jul 11, 2025: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series C Convertible Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eugene Frederick Leffler, III · Executive Officer
  • Hermann Luebbert · Executive Officer, Director
  • Beth J. Hoffman · Director
  • Heikki J. Lanckriet · Director
  • John J. Borer III · Director
  • Kevin D. Weber · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The issuer agreed to sell up to 11,000 shares of its Series C Convertible Preferred Stock & issue such shares in two tranches of 8,500 shares & 2,500 shares, respectively, as disclosed in a Current Report on Form 8-K filed with the SEC on July 1, 2025.”
  • On a merger: “The funds raised in the offering will be used, at least in part, to pay costs related to the acquisition of all U.S. assets related to certain products & associated patents as disclosed in a Current Report on Form 8-K filed with the SEC on June 30, 2025.”

Signed by E. Fred Leffler, III, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 11, 2025. Read the notice at the SEC.

equitySEC
Feb 2024$8 MPrivate placement after listing$2 to $10 million

Biofrontera Inc.: Private sale, Feb 2024

Investors in this round

8 investors had bought by the notice of Mar 5, 2024: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$685,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eugene Frederick Leffler, III · Executive Officer
  • Hermann Luebbert · Executive Officer, Director
  • Beth J. Hoffman · Director
  • Heikki J. Lanckriet · Director
  • John J. Borer III · Director
  • Kevin D. Weber · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Roth Capital Partners, LLC (CRD 15407) · Newport Beach, CaliforniaSold in MD, NV, NY, and outside the US

Remarks in the notice

  • On the amounts: “The Company sold approximately 6,586 shares of Series B-1 Convertible Preferred Stock and warrants to purchase shares of Series B-3 Convertible Preferred Stock as first disclosed on its Current Report on Form 8-K filed with the SEC on February 20, 2024.”

Signed by E. Fred Leffler, III, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 5, 2024. Read the notice at the SEC.

equity, optionsSEC
Oct 2022$4 MPrivate placement after listing$2 to $10 million

Biofrontera Inc.: Private sale, Oct 2022

Investors in this round

1 investor had bought by the notice of Nov 4, 2022: 0 accredited, 1 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Erica F Gates · Executive Officer · Senior Director Finance of Biofrontera Inc.
  • Erica L Monaco · Executive Officer · Chief Executive Officer of Biofrontera Inc.
  • Eugene Frederick Leffler · Executive Officer · Chief Financial Officer of Biofrontera Inc.
  • Hermann J Luebbert · Executive Officer, Director · Executive Chairman and Director of Biofrontera Inc.
  • Beth J Hoffman · Director
  • John J III Borer · Director
  • Kevin D Weber · Director
  • Loretta M Wedge · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Reflects a privately negotiated exchange of 3,148,042 shares of Biofrontera Inc. common stock for an option to acquire 2,623,365 shares of Biofrontera AG. Offering amount based upon closing price of Biofrontera Inc. on 10/25/2022 ($1.17).”

Signed by Erica Monaco, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 4, 2022. Read the notice at the SEC.

equitySEC
Jul 2022$7 MPrivate placement after listing$2 to $10 million

Biofrontera Inc.: Private sale, Jul 2022

Investors in this round

1 investor had bought by the notice of Aug 11, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Erica F Gates · Executive Officer
  • Erica L Monaco · Executive Officer
  • Hermann J Luebbert · Executive Officer, Director
  • Beth J Hoffman · Director
  • John J III Borer · Director
  • Kevin D Weber · Director
  • Loretta M Wedge · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total offering amount and total amount sold includes warrants to purchase 4,285,715 shares of common stock. See the Company's Form 8-K filed with the SEC on July 28, 2022 regarding the transaction.”

Signed by Erica Monaco, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 11, 2022. Read the notice at the SEC.

equity, optionsSEC
May 2022$9 MPrivate placement after listing$2 to $10 million

Biofrontera Inc.: Private sale, May 2022

Investors in this round

1 investor had bought by the notice of May 23, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$660,123
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Erica F Gates · Executive Officer
  • Erica L Monaco · Executive Officer
  • Hermann J Luebbert · Executive Officer, Director
  • Beth J Hoffman · Director
  • John J III Borer · Director
  • Kevin D Weber · Director
  • Loretta M Wedge · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • The Benchmark Company, LLC (CRD 22982) · New York, New YorkSold in NY
  • Roth Capital Partners, LLC (CRD 15407) · Newport Beach, CaliforniaSold in NY

Signed by Erica Monaco, Chief Executive Officer. Source: SEC Form D, newest notice filed May 23, 2022. Read the notice at the SEC.

equity, optionsSEC
Nov 2021$15 MNo. 1$10 to $50 million

Biofrontera Inc.: Raise no. 1, Nov 2021

Investors in this round

1 investor had bought by the notice of Dec 10, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,198,794
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Erica F Gates · Executive Officer
  • Erica L Monaco · Executive Officer
  • Hermann J Luebbert · Executive Officer, Director
  • Beth J Hoffman · Director
  • John J III Borer · Director
  • Loretta M Wedge · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Roth Capital Partners, LLC (CRD 15407) · Newport Beach, CaliforniaSold in NY
  • The Benchmark Company, LLC (CRD 22982) · New York, New YorkSold in NY

Signed by Erica Monaco, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 10, 2021. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Biofrontera Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2025).

    SEC Form D · Jul 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2025

That is all the official record says: Biofrontera Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Biofrontera Inc. are on record.

Investors#

No investor of Biofrontera Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 1 investors.

Largest shareholders today

Institutions holding Biofrontera Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Biofrontera Inc.
NameRoleNamed in
Eugene Frederick Leffler, IIIExecutive officerJul 2025
Hermann LuebbertExecutive officerJul 2025
Erica F GatesSenior Director Finance of Biofrontera Inc.Nov 2022
Erica L MonacoChief Executive Officer of Biofrontera Inc.Nov 2022
Eugene Frederick LefflerChief Financial Officer of Biofrontera Inc.Nov 2022
Hermann J LuebbertExecutive Chairman and Director of Biofrontera Inc.Nov 2022
Beth J. HoffmanDirectorJul 2025
Heikki J. LanckrietDirectorJul 2025
Hermann LuebbertDirectorJul 2025
John J. Borer IIIDirectorJul 2025
Kevin D. WeberDirectorJul 2025
Beth J HoffmanDirectorNov 2022
Hermann J LuebbertExecutive Chairman and Director of Biofrontera Inc.Nov 2022
John J III BorerDirectorNov 2022
Kevin D WeberDirectorNov 2022
Loretta M WedgeDirectorNov 2022

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.